Kiora's KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model
KPRX sits 46% above its 52-week low of $1.765.
Summary
Kiora Pharmaceuticals reported positive preclinical data for its drug candidate KIO-300, demonstrating significant suppression of seizure activity in an ex vivo epilepsy model. This expands the potential therapeutic applications of KIO-300 beyond its current Phase 2 program for vision restoration. The findings suggest a broader utility for the company's ion channel modulator platform in neurological disorders.
At the time of this announcement, KPRX was trading at $2.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.76 to $3.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.